pelabresib
Sponsor Novartis AG · listed as NVS
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
pelabresib is a clinical-stage drug asset sponsored by Novartis AG, listed as NVS. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jun 2, 2027 (day precision, medium confidence), tied to trial NCT06401356. The asset is in Phase 3 and currently recruiting, studied in Hematologic Malignancy.
Next catalyst
Event typeREADOUT
Expected date2027-06-02
As disclosedJun 2, 2027
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06401356
PhasePHASE3
StatusRECRUITING
Lead sponsorNovartis Pharmaceuticals
Listed asNVS
Condition(s)Hematologic Malignancy; Solid Tumor; Advanced Malignancies
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More NVS catalysts